These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

884 related articles for article (PubMed ID: 31099674)

  • 1. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
    Fares CM; Van Allen EM; Drake CG; Allison JP; Hu-Lieskovan S
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():147-164. PubMed ID: 31099674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
    Gide TN; Wilmott JS; Scolyer RA; Long GV
    Clin Cancer Res; 2018 Mar; 24(6):1260-1270. PubMed ID: 29127120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Firing Up Cold Tumors.
    Cheng WC; Ho PC
    Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
    Georganaki M; van Hooren L; Dimberg A
    Front Immunol; 2018; 9():3081. PubMed ID: 30627131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired resistance to cancer immunotherapy.
    Draghi A; Chamberlain CA; Furness A; Donia M
    Semin Immunopathol; 2019 Jan; 41(1):31-40. PubMed ID: 29968044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
    Duan J; Wang Y; Jiao S
    Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
    Wilky BA
    Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer.
    Bakacs T; Moss RW; Kleef R; Szasz MA; Anderson CC
    Scand J Immunol; 2019 Dec; 90(6):e12821. PubMed ID: 31589347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic correlates of response to immune checkpoint blockade.
    Keenan TE; Burke KP; Van Allen EM
    Nat Med; 2019 Mar; 25(3):389-402. PubMed ID: 30842677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.
    Asmar N; Ibrahim T; Rey JF
    Dig Dis Sci; 2018 Sep; 63(9):2177-2179. PubMed ID: 29982987
    [No Abstract]   [Full Text] [Related]  

  • 11. Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer.
    Shevchenko I; Bazhin AV
    Front Immunol; 2018; 9():1816. PubMed ID: 30131808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
    Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
    J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
    De Wispelaere W; Annibali D; Tuyaerts S; Lambrechts D; Amant F
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hallmarks of response to immune checkpoint blockade.
    Cogdill AP; Andrews MC; Wargo JA
    Br J Cancer; 2017 Jun; 117(1):1-7. PubMed ID: 28524159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
    Saleh R; Elkord E
    Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.
    Chae YK; Oh MS; Giles FJ
    Oncologist; 2018 Apr; 23(4):410-421. PubMed ID: 29242279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory T cells in cancer; can they be controlled?
    Adeegbe DO; Nishikawa H
    Immunotherapy; 2015; 7(8):843-6. PubMed ID: 26316166
    [No Abstract]   [Full Text] [Related]  

  • 20. Tackling Resistance to Cancer Immunotherapy: What Do We Know?
    Gondhowiardjo SA; Handoko ; Jayalie VF; Apriantoni R; Barata AR; Senoaji F; Utami IJW; Maubere F; Nuryadi E; Giselvania A
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32911646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.